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N AVERAGE adult at rest consumes approximately A 100 million trillion molecules of oxygen per second; 
with virtually no capacity for oxygen storage, cessation of 
oxygen delivery quickly results in irreversible cellular dam- 
age. The human cardiopulmonary system functions remark- 
ably well in healthy individuals, maintaining the mitochon- 
drial oxygen tension (greater than 1 mmHg) required for 
aerobic metabolism. In the critically ill and in anesthetized 
patients, however, any acute dysfunction may result in 
hypoxia. The need for oxygen measurement in blood was 
long apparent, but it was not until Clark developed the 
polarographic electrode in the 1950s that this became 
routinely available in the clinical setting.’ With the addition 
of the carbon dioxide electrode by John Severinghaus in 
1958, the blood gas analyzer was developed.2 Today it is 
difficult to imagine treating patients in an acute care setting 
without the immediate availability of blood gas analysis. 
Still, there are limitations in using intermittent measure- 
ment to evaluate such a dynamic system. Ideally, blood gas 
data would be provided continuously so that oxygenation, 
ventilation, and acid-base status could be monitored and 
adverse changes treated before impacting the patient’s 
overall condition. Decreasing the number of blood samples 
drawn would provide other benefits such as decreasing the 
risk of iatrogenic infection or anemia, exposure of person- 
nel to blood-borne diseases, and the possibility of analysis 
error. 
Continuous noninvasive monitoring of oxygenation and 
ventilation with pulse oximetry and capnography represents 
a substantial improvement in patient monitoring but does 
not replace arterial blood gas and pH analysis. For nearly 
two decades efforts have been made to adapt the electro- 
chemical sensors used in in vitro blood gas measurements to 
continuous in vivo monitoring, but these efforts have met 
with limited success.3-5 Over the past 5 years, significant 
advances in continuous blood gas monitoring have been 
made using photochemical sensors, often called “optodes.” 
This article will first briefly review the electrochemical 
technology used in blood gas analyzers, and then describe 
the development and design of optically based sensors. This 
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discussion will conclude with a review of the current clinical 
performance data and present the different manufacturers’ 
monitors, which are in various stages of clinical develop- 
ment. 
ELECTROCHEMICAL SENSORS 
Electrochemical devices, or electrodes, measure a small 
current or voltage resulting from a chemical reaction at the 
sensor surface. The substance being measured is not only 
involved in the reaction, but its concentration is the “rate- 
limiting” constituent of the reaction. The current or voltage 
change produced by the reaction is calibrated to the 
concentration of the substance being measured. In 1956, 
Leland Clark presented a small electrochemical sensor 
composed of a platinum cathode and silver anode’ (Fig 1). 
A polarizing potential is maintained between the two 
electrodes, which are covered with an oxygen-permeable 
membrane and then immersed in an electrolyte solution. 
Oxygen diffuses into the electrode cell and the following 
reaction takes place at the cathode surface: 
0, + 2H,O + 4e- -j 40H- (1) 
The current produced by this reaction is proportional to the 
oxygen partial pressure. This oxygen electrode has been 
used to measure oxygen tension in the gas or liquid phase 
ever since its initial description. 
At the time Clark described his oxygen electrode, mea- 
surement of pH was accomplished with the “pH-sensitive 
glass” electrode. When this pH electrode is placed in a 
solution, a small voltage proportional to the hydrogen ion 
concentration develops between the electrode and a refer- 
ence ground. In 1958 John Severinghaus presented a 
method of measuring carbon dioxide partial pressure using 
the available pH glass electrode placed in a buffered 
electrolyte ce11.2 CO2 diffusing through a membrane into 
the electrolyte cell reacts with water producing carbonic 
acid thus changing the pH of the cell. This pH change is 
measured with the glass pH electrode, and the CO* partial 
pressure is referenced to the voltage change as measured by 
the pH electrode. By 1960, these three electrodes had been 
placed into one device and the blood gas analyzer was born. 
Over the past 30 years, attempts have been made to 
miniaturize these electrodes for continuous in vivo monitor- 
ing of blood gases. Because the sensing element in the pH 
and PC02 electrodes is glass, these devices were never 
viable candidates for intravascular sensors. The primary 
problem of electrochemical intravascular PO2 monitoring 
has been miniaturization of the Clark electrode. This 
problem has been approached in two ways. In one method 
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Fig 1. (A) Schematic of a Clark poiarographic oxygen electrode. 
The circuit consists of a voltage source (battery) and a current meter 
connecting platinum and sihrer electrodes. The electrodes are im- 
mersed in an electrolyte cell. A membrane permeable to oxygen but 
not to the electrolyte covers one rurface of the cell. Oxygen dlluses 
through the membrane and reacts with water at the platinum cathode 
to produce hydroxyl ions. The ammeter measures the current pro- 
duced at the cathode by the electrons consumed In this reaction. (B) A 
plot of current produced as a function of the voltage between the two 
electrodes (polarizing voltage). This plot is called a polarogram. in the 
range near 880 mV there is a plateau in the polarogram that occurs at 
higher currents as the PO, in the ceil is increased. Most poiarographic 
oxygen electrodes use 600 to 800 mV polarizing voltage to obtain a 
stable current at each PO*. 
the platinum cathode is covered by an oxygen-permeable 
membrane and inserted into the blood stream whereas the 
anode is applied topically to the skin surface.5 In the second 
approach, both the anode and cathode are miniaturized to 
Fig 2. Transmission of light 
by flberoptic strand. Nearly com- 
plete internal reflection can be 
achieved if the cladding material 
has a refractfve index (pz) that is 
much greater than that of the 
core material (p,). These fibers 
can be produced with very small 
diameters (c 1 pm) and yet trans- 
mit light with very high effi- 
ciency. 
produce a small intra-arterial probe, which is surrounded 
by electrolyte solution and covered by a membrane. Al- 
though data have been reported from clinical studies using 
both approaches, the accuracy has not been promising, with 
problems related to technical difficulties with electrode 
placement, drift, thrombus formation, emboli, and interfer- 
ence with arterial waveforms.3-5 Even if these problems are 
overcome by increased miniaturization, intra-arterial elec- 
trochemical measurement of pH and PC02 is not feasible. 
In spite of the difficulty experienced translating these 
electrochemical devices to intravascular monitors, they 
remain the mainstay of blood gas analyzer technology 
today. 
PHOTOCHEMICAL SENSORS: OPTODES 
Just as electrodes quantify the concentration of the 
substance being measured on the basis of electrochemical 
(voltage or current) changes, optodes quantify concentra- 
tions on the basis of photochemical reactions, which pro- 
duce changes in light absorption, light reflection, or light 
emission (luminescence or fluorescence). The two basic 
components of a photochemical sensor are the optical 
fibers that transmit light with high efficiency and the specific 
photochemical dyes. This section will first discuss the 
principles of fiberoptic light transmission and photochemi- 
cal dyes, and then describe how the two are configured to 
produce a sensor. 
Optical fibers work on the principle of total internal 
reflection (Fig 2). These fibers consist of a central core of 
glass or plastic that is clad with another material whose 
refractive index is much higher than that of the core 
material.6 The refractive index of a substance, u (which is 
dimensionless) is the speed of light in a vacuum (C) divided 
by the speed of light in that substance (V): 
C 
c”=v 
When the l.~ of the cladding material is much greater than 
the l.~ of the core material, light striking the interface 
between the two is nearly completely internally reflected, 
resulting in efficient transmission of light down the fiber. 
Over the past two decades optical fibers have become 
ubiquitous in almost every industry. 
The second critical material for development of optodes 
is the photochemical dye. When photons strike a substance, 
Refractive index of core (~1) 
Refractive index of cladding (~2) 





the light can be transmitted, reflected, absorbed, or ab- 
sorbed and re-emitted.7J Substances that re-emit absorbed 
light are called fluorescent, phosphorescent, or lumines- 
cent, depending on the photochemical properties of the dye 
invo1ved.s When the energy of a photon is absorbed by a 
luminescent dye, electrons in the dye are elevated to a 
higher energy state. After a small time lag, that photon of 
light is re-emitted as the electron drops back to its ground 
state (Fig 3). In certain dyes this re-emitted energy can be 
absorbed by oxygen molecules, “quenching” the intensity of 
the luminescent signal.9J0 The intensity of the luminescent 
signal reliably decreases as the concentration of oxygen 
increases. The theoretical relationship between lumines- 
cent intensity and oxygen concentration is given by the 
Stern Volmer equation: 
Lo 
y = K(P03 + 1 
where Lc is the intensity of the luminescent signal in the 
absence of oxygen, L is the intensity of the signal in the 
presence of oxygen, and K is the quenching constant. 
Equation 3 can be rearranged to the following: 
The degree of change in the intensity of luminesced light is 
much greater at low concentrations of oxygen than at higher 
ones, indicating that the luminescent quenching techniques 
would be more accurate at low oxygen tensions. The 
luminescence quenching method for measurement of oxy- 
gen tension has been known for years but its application 
with optical fibers to produce oxygen sensors has come 
about only in the past decade.6*9-12 An oxygen probe can be 
constructed by placing an oxygen-sensitive dye (with a 
Fig 3. The fluorescence quenching phenomenon. 
An electron of the fluorescent dye is excited to a 
higher energy level by an incident photon (v,). This 
excited electron can return to a lower energy level by 
either emitting a photon (v2) or interacting with an 
oxygen molecule and raising the latter to a higher 
vibrational energy level. (Reprinted with permis- 
sion.‘) 
known quenching constant, K) at the tip of a fiberoptic 
strand. A xenon lamp emits light of a known intensity down 
the fiberoptic strand, and the dye re-emits an intensity of 
light back up the strand proportional to the oxygen tension 
surrounding the dye. 
PO2 optodes were initially based upon quenching of 
luminescence intensity as described above. A second means 
of determining partial pressure of oxygen with optodes is 
based on the known time lag from excitation to re-emission 
of the photon, known as the “luminescence lifetime.“12 This 
“lifetime” is reliably altered in the presence of oxygen, and 
PO2 therefore can be determined by pulsing incident light 
and measuring the shift in luminescence lifetime. The 
equation describing the relationship between PO;, and the 
lifetime shift is: 
where to is the luminescence lifetime in the absence of 
oxygen, t is the measured luminescence lifetime in the 
presence of oxygen, and k is a luminescence time constant. 
The theoretical advantage of using a “time shift” method to 
measure PO2 versus intensity quenching is that intensities 
of light can be distorted not only by oxygen quenching, but 
also by bending of the optical fiber, dye photobleaching and 
misalignment of optical connectors; time shift measure- 
ments are not affected by these practical considerations.12 
Thus, when luminescence intensity is used, a second dye is 
required whose luminescence is unaffected by the presence 
of oxygen, thus providing a reference intensity to account 
for the losses of light intensity due to fiberoptic transmis- 
sion characteristics. 
Photochemical sensors that measure pH use either fluo- 
rescent or absorbance technology.13-l5 Fluorescent dyes 
EMERGING TECHNOLOGIES 345 
Fig 4. Schematic diagram of various probe geo- 
metrks, inclm monoflber, dual fiber, continuous 
transmksion (bent fiber), and probe using circumfer- 
ential incorporation of dye matrix into covering of 
optk fiber. (A) dual fiber; (B) monofiber; (C) transmis- 
sion; (D) monofiber with circumferential analyzing 
chamber. 
inalyzing 
suitable for use in pH sensors are those that exist in both 
acidic and basic forms, and the proportion of the dye in 
each form at any time corresponds to the hydrogen ion 
concentration. The acidic form of the dye has a maximum 
excitation frequency different from that for the basic form 
of the dye. The fluorescence intensity observed at each 
excitation frequency therefore defines the portion of dye 
existing in the basic versus acidic form, and pH is based on 
the ratio of the fluorescent intensity returned from each of 
the two exciting frequencies. Using this ratio method 
eliminates the problems of light intensity loss due to 
mechanical problems. Light absorbance can also be used to 
determine pH. An indicator such as phenol red absorbs a 
variable portion of green light (wavelength 558 nm) depend- 
ing on the hydrogen ion concentration. Red light at a 
wavelength 600 nm is not absorbed at all. The device 
alternately flashes red and green light, and the proportion 
of green light absorbed relative to the reference red light is 
used to calculate pH. 
The carbon dioxide photochemical sensor is based on the 
same secondary sensing principle described by Severing- 
haus15 for the electrochemical PC02 sensor. A pH-sensitive 
optode is bathed in a buffering solution and coated with a 
hydrophobic silicone layer permeable to CO*. The CO2 
rapidly equilibrates across the silicone matrix, is buffered, 
and the resulting pH change, measured by either fluores- 
cence or absorbance technology, is calibrated to PC02. 
Because of the inherent characteristics of fiberoptics and 
photochemical dyes, fluorescent optodes offer a number of 
advantages over other possible sensor designs. They are 
uniquely suited for miniaturization because of the availabil- 
ity of very small diameter yet reliable optical fibers (as small 
as 50 to 100 km). The dyes used to measure gas tensions are 
stable over time, are biocompatible (nontoxic to the pa- 
tient, and not affected by the patient environment), have a 
fast response time to changes in concentration of the 
measured substance (60 to 90 set), and are not consumed 
by the measurement process. The probe assembly is rela- 
tively simple and fairly immune to interference from the 





expose the patient to electrical risk and are immune to 
electrical noise. Despite the inherent simplicity of optodes, 
the geometry of the optical fibers and the characteristics of 
the photochemical dye substances have posed substantial 
technical problems that have been addressed in a variety of 
ways by manufacturers of these devices. 
GENERAL SYSTEM DESIGN CONSIDERATIONS 
Sensor Probe Design 
Both the delivery of the excitation light and the recovery 
of the emission light must occur with high energy efficiency 
to maximize accuracy. The energy efficiency is altered by 
fiberoptic geometry and by both the number of optical 
connections and the length of the optical cable through 
which the beam is carried. Various fiberoptic light transmis- 
sion geometries are schematically illustrated in Fig 4. Both 
dual and monofiber systems have the indicator dye located 
at the tip of the probe, a geometry with inherent loss of 
signal energy. Dual fibers transmit and receive light simulta- 
neously, whereas monofiber systems alternatively send and 
receive. A transmission geometry using a 180” bend in the 
fiber with the analyzing chamber at the side of the probe 
improves emission (returning) signal strength. The final 
design uses indicator impregnated circumferentially in the 
cladding of the fiber. This is also said to improve the 
strength of the returning signal. With any one of the above 
geometries, the strength of the excitation light signal is high 
but the energy of the emission light is considerably dimin- 
ished via the losses in the analyzing chamber (either 
quenched as in the oxygen probe or absorbed as in pH and 
carbon dioxide probes) and through the tip of the fiber. 
Therefore, the length of the fiber carrying light to the 
patient has less impact than the length of the fiber that 
carries the returning light signal to the detector. Most 
monitoring systems consist of four components as shown in 
Fig 5 and as described below: the analyzer, the interface 
module, the display module, and the sensor probe. The 
interface module contains the optical multiplexer and the 
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emission detector, and is located as close to the patient 
probe as technically feasible. 
Analyzer 
The analyzer contains the light source and the micropro- 
cessor responsible for system function control, data process- 
ing, and analysis of results. Light of the appropriate 
wavelength is sent from the high-output light source through 
a lens to focus it into the interface fiberoptic cable and thus 
to the interface module. 
Interface Module 
The interface module, although complex, is still small 
enough to be located in close proximity to the patient. It 
consists of the optical multiplexer, the analog front end, 
and a digital converter. The optical multiplexer receives the 
excitation energy sent from the light source and passes the 
light through a lens for collimation. The collimated beam 
then passes through a beam splitter so that a portion of the 
light is sent to a reference detector for monitoring lamp 
output, while the remainder of the beam is focused into the 
optical fiber of the probe and sent to the analyzing 
chamber. The light emitted from the photochemical dye is 
returned along the same fiber and is focused by the beam 
splitter onto a broad band width detector (photo diode) for 
conversion from an optical to an electrical signal. This 
analog electrical signal is then amplified and filtered until it 
is acceptable for digital conversion and the digital signal is 
transmitted to the microprocessor. 
Display Module 
The digital signal received in the microprocessor is 
referenced both to the input lamp intensity and the refer- 
Fig 5. Schematic of a typical 
continuous intra-arterial blood 
gas monitor, consisting of the 
display module, the analyzer, the 
interface module, and the dispos- 
able patient probe (IV). 
ence light intensity before conversion via algorithm to a 
recognizable blood gas value for display on the monitor. 
When a change in blood gas tension is detected, most 
systems will display the appropriate up or down arrow until 
equilibrium is reached (generally within 60 to 90 seconds). 
Sensor Probe 
The patient sensor probe, as shown in Fig 6, consists of 
three individual fiberoptic strands, each with its specific dye 
covering at the tip. In addition to the fiber bundles required 
for P02, PC02 and pH determination, blood temperature 
must also be continuously monitored as gas solubilities and 
pH change with temperature. A thermocouple is therefore 
imbedded in the fiberoptic sensor to provide a continuous 
measurement of blood temperature at the analyzing cham- 
ber. 
Each patient probe is supplied with a calibration device 
both to ensure accurate calibration prior to insertion and to 
prevent dehydration of the probe during shipping and 
storage. Currently, a two-point tonometer gas calibration is 
required for most systems and is accomplished by bubbling 
two known concentrations of gas in sequence through the 
probe while in the calibrating device. This in vitro calibra- 
tion system is very similar to those used for calibration of 
bench blood gas analyzers. These systems may also be 
calibrated as needed in vivo to laboratory arterial blood gas 
determinations. 
EXPERIMENTAL AND CLINICAL STUDIES 
As shown in Table 1, optimal probe design would include 
the following properties: quadruple function (PO*, PCO;?, 
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Fig 6. Schematic of a four component sensor probe for determination of PO*, PCO,, pH, and temperature. 
insertion through a 20-gauge radial artery catheter without 
altering transduced pressure, nonthrombogenic and non- 
toxic (heparin bonded), unaffected by blood or drugs, 
sensitive, specific, accurate without drift, rapid response, 
inexpensive, and easy to use. Although all of these goals 
have not been accomplished to date, substantial progress 
has occurred over the past few years. The following section 
will review the accuracy data, which have been presented in 
the scientific literature using various optode probes. Before 
the specific data are presented, the most common statistical 
methods used to assess accuracy will be briefly reviewed, 
because many of the articles use different methods making 
it difficult to compare data from different studies. 
Evaluation of the accuracy of a new measurement device 
usually involves determining values with the new instru- 
Table 1. Desirable Characteristics of a Continuous Intra-Arterial 










Be highly accurate with good precision and reliability 
Have little or no drift over 46 to 72 hours 
Have a rapid response time (20 to 60 set) 
Be compatible with existing arterial catheter systems (20 gauge) 
without interfering with transduced pressures or withdrawal of 
blood samples. 
Be biocompatible and nonthrombogenic 
Be unaffected by conditions of high or low cardiac output, or 
shock states 
Be easy to use and maintain 
Be cost effective, either reducing laboratory determination or 
reducing patient care costs 
Have a small footprint, given the space constraints of most ICU or 
OR conditions 
ment and comparing them with ones derived from the 
existing technology. In this case the bench blood gas 
machine is considered to be the gold standard by which all 
blood gas monitors will be measured. Although the blood 
gas machine is a very reliable device, any device will have a 
certain degree of acceptable error. In the case of blood gas 
machines, electrode precision using standard electrolyte 
solutions are as follows: pH t 0.01 unit, PC02 5 2% 
(approximately ? 1 mmHg at 40 mmHg) and POr rf: 3% 
(approximately 2.5 mmHg at 80 mmHg; over 150 mmHg, 
the precision is *lo%) .16 Variability using actual blood 
samples may be greater, especially considering preanalytic 
error such as air in the syringe, inappropriate volume of 
heparin for the volume of blood, and time delay from 
sampling to measurement. Thorson et all7 drew an arterial 
sample each 10 minutes for 1 hour in 29 stable intensive 
care unit (ICU) patients, then analyzed each sample two 
times on the same blood gas analyzer.” The range separat- 
ing the highest and lowest PO* in any one patient over the 
hour varied from 1 to 45 mmHg, and PC02 varied from 1 to 
8 mmHg. The average percent change in PO* between 
sequential intrapatient samples was 5.3 + 2.8%. Despite 
the known variability in gas machine values, the accuracy of 
intravascular blood gas optodes has been and will continue 
to be assessed by how well they agree with bench arterial 
blood gas analysis. 
The classic statistical method for comparison of values of 
two continuous variables from two different measurement 
devices is linear regression. The linear regression correla- 
tion coefficient assesses how well values measured with the 
new device follow changes in values determined by the 
standard device. An example of linear regression data 
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Fig 7. Linear regression plots showing optode values (Po02, 
PoC02, plio) and simultaneous in vitro analyzer values (Pa02, PaC02, 
pHa); 14 patients, N = 87. Line of identity, ----; linear regression, -. 
(Reprinted with permission. International Anesthesia Research Soci- 
ety.*‘) 
taken from a study by Barker et alzl is shown in Fig 7. A 
correlation coefficient value close to one (for example, 
r = 0.98) demonstrates a very high degree of positive 
association, ie, when one increases, so does the other. 
Correlation coefficients, however, do not indicate how 
much one will rise when the other rises or how closely the 
numerical values agree. Another weakness of the linear 
regression method for comparison of accuracy of two 
methods of measure is that the r value is significantly 
affected by the range over which the data are collected. For 
example, if 10 blood gas samples show PC02 values be- 
tween 40 and 42 mmHg and the optode readings are also 
between 40 and 42 mmHg, it is very difficult to determine 
the slope of the line connecting these data. If, however, 
arterial blood gas samples are collected where the PO;! 
values range from 60 to 400 mmHg, it will be easy to 
demonstrate a high degree of association (an r value close 
to 1) with an optode device that works to any degree, even 
with great variability between measured values. 
When trying to determine if a new method of measure is 
of sufficient accuracy to replace an older method of 
measure, it is useful to know how well the two measurement 
values agree over the range of clinical interest. Altman and 
Bland’* have suggested a simple method of assessing this 
type of agreement using bias and precision. Bias, the mean 
difference between the paired values, represents the system- 
atic error between two measurement methods, eg, does the 
optode consistently overestimate or underestimate the 
blood gas machine? This systematic error can be corrected 
by recalibrating the device. Precision is the standard devia- 
tion of the differences, and provides a measure of the 
random error inherent in the device. Random error cannot 
be corrected. A trusted device must have a very small 
precision. Altman and Bland also suggest plotting the data 
on a bias plot: the difference of the two values on the 
vertical axis versus the mean of the two values on the 
horizontal axis, with a horizontal line at the zero difference 
point representing the ideal. The bias plots shown in Fig 8 
are from the same study as the linear regression graphs 
shown in Fig 7, illustrating the information gained by the 
different statistical methods. Finally, if the bias changes 
with time, the instrument is said to drift. Significant drift 
would require recalibration at frequent intervals, somewhat 
defeating the purpose of having continuous data. 
Clinical Studies 
In spite of the enthusiasm over intravascular blood gas 
monitoring with optodes, there are only a few clinical 
studies to date that assess accuracy, a few case reports that 
may demonstrate utility, and no data that address cost/ 
benefit issues. The first clinical study on a triple-function 
optode, conducted in both dogs and humans, was presented 
by Shapiro et al in 1989.19 The probe, a 0.62-mm diameter 
optode (CDI-3M Healthcare, Tustin, CA), was inserted 
through a 20-gauge arterial catheter. This first study used 
optodes calibrated in vivo to a bench blood gas analyzer and 
79 blood samples collected from 12 critically ill patients 
over 3 to 26 hours. The bias and precision data were pH 
0.002 2 0.02, PaCOz 0.44 r 2.97 mmHg, and PaOr 1.22 ? 
9.34 mmHg (Table 2). The excellent bias data arise from 
calibration of each probe in vivo with a bench blood gas 
analyzer first, and elimination of 13 probes because they did 
not calibrate. Five of the 12 probes that did calibrate failed 
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Fig 8. Bias plots showing values of error (PoO, - PaO,, 
PoC02 - P&O, pHo - pHa) plotted versus in vitro analyzer values 
(PaO, PaC02, pHa); 14 patients, N = 87. Bias or mean error, ----; f 
pmcision, . . . . (Reprinted wkh permission. International Anesthesia 
Research Society.“) 
during the study and were dropped from analysis. The 
authors concluded that further study was warranted.t9 
Early clinical studies suffered from acute decreases in the 
oxygen optode measurement unrelated to arterial PO2 
changes (Figs 9, 10). Mahutte et alZO placed oxygen optode 
probes in 18 volunteers. They found two causes for these 
rapid and unpredictable decreases in PO* measurement. 
Clot formation at the tip of the sensor caused a “down-up- 
down” pattern with decreased POz, increased PC02, and 
decreased pH (Fig 9). Acute decreases in oxygen measure- 
ment could be produced when the probe was adjacent to 
the arterial vessel wall (Fig 10). Slight retraction of the 
probe returned the PO2 value to normal. Thus, the distance 
the probe protruded beyond the cannula was critical: 
overextension caused a wall effect (unpredictable decreases 
in oxygen values), whereas retraction too far within the 
cannula produced values contaminated by the flush solu- 
tion. Investigation of this “wall effect” proceeded with a 
special probe with three oxygen sensors 120” apart on the 
sides of the sensor tip. Rotation of the probe produced the 
POz “down” pattern as each sensor found the vessel wall, as 
shown in Fig 10. Table 2 contains the bias and precision 
data: pH 0.003 + 0.02, PC02 0.77 ? 2.44 mmHg, PO* 2.9 2 
25.4 mmHg. These optodes were calibrated prior to inser- 
tion into the patient by the tonometer system provided. 
This study by Mahutte et al describes a crucial clinical 
application flaw in the probes tested at that time: acute, 
unpredictable, highly significant decreases in PO2 could be 
produced solely by position changes of the probe. These 
decreases were unrelated to any actual change in the 
patient’s arterial oxygenation. The authors postulated means 
of correcting this problem of “wall effect” using various 
probe geometries, but little data exist in the literature 
demonstrating that altering the probe geometry does, in 
fact, obviate this problem. 
Barker and Hyatt conducted a third clinical study intraop- 
eratively using the same CDI3M optode. That optode 
required an 18-gauge radial artery catheter. Eighty-seven 
arterial blood samples were compared to optode values; no 
acute decreases in PO2 occurred. Bias and precision data 
revealed pH -0.032 + 0.042, PaC02 -3.8 * 4.7 mmHg, 
and PaOz -9 + 23.3 mmHg (Table 2). Note the negative 
bias values for each variable. Although these data demon- 
strate improved accuracy, the need for an 18-gauge catheter 
reduced the clinical desirability of this CDI3M probe. 
Recently, CDI3M presented an ex vivo, on demand, 
arterial blood gas monitoring system. That company contin- 
ues to develop its intra-arterial probe, which may or may 
not resemble the probe used in the Barker and Hyatt study. 
The largest human study to date on an optode blood gas 
system is the multicenter trial of the ex vivo CD1 2000 Blood 
Gas Monitoring System (CDI3M Healthcare, Tustin, CA).22 
This system has the sensing chamber located outside of the 
body. When analysis is desired, a technician withdraws an 
arterial sample into the sensing chamber; results are 
displayed after approximately 2 minutes. This design miti- 
gates thrombogenicity and arterial wall interference, but 
represents a measurement rather than a monitoring tech- 
nique. Nonetheless, response time is fast enough to permit 
very frequent (many times per hour) sampling while preserv- 
ing test reliability and protecting both patients and person- 
nel from risk of blood-borne infections. The results from 
this study included 1,341 samples drawn from 117 patients 
over 80 hours. The bias and precision values shown in Table 
2 demonstrate reasonable accuracy. 
Zimmermann and Gellinger presented data on a triple 
optode probe produced by Optex Corporation (The Wood- 
lands, TX). One hundred four blood samples from five 
critically ill patients monitored over 68 hours were com- 
pared to two different bench top blood gas analyzers. The 
bias and precision values were -0.021 2 0.037 for pH, 1.74 
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Author 
Table 2. Summary of Human Clinical Studies 
___~__ 
PO2 PCOl PH 
Probe 6-P r N BtP r N BkP r N Subject Callbratlon 
Shapiro’9 (1989) CDI -17 t 46 0.96 256 l-+4 0.95 359 -0.02 + 0.03 0.97 420 Dog In vitro 
-l-+9 0.99 79 0.44 + 3 0.96 79 0.002 * 0.02 0.97 79 Humant Invivo 
Mahutte*O (1990) CDI -3 + 25 0.99 48 0.8 ? 2.4 0.98 48 0.003 + 0.2 0.98 48 Human In viva 
Larso+ (1990) PB 3.0% * 3%* 0.99 76 5.1% 2 5.1%X 0.92 93 Human Unknown 
Barker21 (1991) CDI -9 t 23 87 -3.8 f 4.6 0.87 -0.03 + 0.04 0.87 Human In vitro 
Zimmermannz4 (1992) CP -2.1 r 13 301 1.5 * 5.5 301 -0.02 + 0.04 301 Human In vitro 
Shapiroz2 (1993) CDI -2.2 + 8.7 0.94 1,341 -0.8 -c 2.2 0.92 1,341 -0.004 + 0.027 0.85 1,341 Human 
Zimmermant+ (1993) CP -5.89 f 13.19 104 1.74 + 6.06 104 -0.021 r 0.037 104 Human 
Abbreviations: CDI, Cardiovascular Devices, Inc 3M; PB, Puritan Bennett; OP, Optex; B, bias; P. precision (*SD of bias); r, correlation coefficient; 
N, number of data points. 
*These values are mean and SD of the absolute value of the differences. No bias information provided. 
tStudy in 12 patients, 5 of 12 probes malfunctioned prior to end of study. 
k 6.06 mmHg for PCO2, and -5.89 2 13.19 mmHg for PO2 
(Table 2). The bias and precision values comparing the two 
blood gas machines were nearly identical to those compar- 
ing the blood gas machine to the optode sensor.23,24 
In both the CDIz2 and 0ptex23 studies probes were 
calibrated in vivo to laboratory determined arterial blood 
gases. No information is provided from either study as to 
the degree of correction required at each calibration (ie, 
what the drift was). Thrombus formation during use of an 
indwelling probe also remains a concern that has not been 
adequately answered to date. In the five patients studied 
with the Optex probe, the authors report no problems with 
arterial waveforms, and no evidence of thrombus. However, 
the number of patients remains small, and none of the 
studies in the literature specifically addresses thrombus 
formation as a study question. For example, no investiga- 
tion included Doppler ultrasound evaluation of vessel 
patency following removal of the arterial cannula or probe. 
Sensors used in the CD1 study were examined microscopi- 
cally for thrombus, but no results are presented other than 
100 z 
to state that no patients were removed from the study due 
to clot formation or sensor failure. 
The literature contains two case reports of continuous 
blood gas monitoring. One case used a CD1 probe during 
single-lung ventilation.25 The other related detection of 
venous air embolism during monitoring with a CD1 probe.26 
These reports may indicate the applicability of these 
monitoring devices to specific cases. 
Variations on a Theme: Current Models 
Based on the studies noted above, numerous companies 
are developing commercially available systems. Given the 
available technology, an ideal system would have the 
characteristics shown in Table 1. The issues of accuracy, 
bias, precision, drift, and performance of indwelling moni- 
tors over a 72-hour period have not yet been addressed 
adequately, as no large in vivo studies have been reported 
on any of the systems. In fact, the total number of patients 
in whom probes have been placed and data collected and 
PCO, 













Fig 9. Pattern of acute 
changes in optode values ob- 
sewed in patients. The oxygen 
tension went down, the carbon 
dioxide went up, and the pfi went 
down. Similar down-up-down 
patterns were observed when 
clots were induced at the probe 
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TIME EACH SEGMENT-6 minutes 
Fig 10. Manipulations wfth prober consisting of three srnsors of oxygen tension arranged in a staggered fashion (A and B) and side-by-side 
(sensors flush at the probe tip) fashion (C). Each probe tip extended beyond the cannula tip. (A) Most dfstal sensor has the lowest orcygan tension 
and is most influm~cad bv relaxation and hyperextension. The most distal sensor extended just beyond the cannula tip. (B) This shows that 180” 
rotatlon raised tha moat dfatal oxygen tansion above that of the most proximal sensor. A subsequent 180” rotation rwersad tha situation. The 
moat proximal sansor extended just beyond the cannula tip. (C) The same effect as in (B) can be obtained wlth 180” rotation in thres sensors flush 
at the probe tip. The probe tip extended slightly beyond the cannula tip. (Reprinted with permission.a) 
presented in peer-review journals appears to be less than 
100. The CD1 ex vivo system has been studied more 
extensively and appears to be accurate over 24 to 72 hours; 
even this system, however, has been used in only about 100 
patients. 
Finally, the most difficult question with this new technol- 
ogy, like many, may be cost/benefit analysis. Given the 
current health care monetary crisis and widespread discus- 
sion concerning apportionment of resources, a new technol- 
ogy needs to be cost-effective either in terms of improved 
mortality or cost savings. Unfortunately, often the capabil- 
ity to perform a test quickly becomes sole justification to do 
so, with no demonstrated improvement in mortality or 
morbidity. Muakkassa et al*’ evaluated ABG use in a 
surgical ICU over a l-year period and showed via multivari- 
able analysis “that the presence of an A-line was the most 
powerful predictor of the number of ABGs drawn per 
patient (P < 0.0001) regardless of all other measures of the 
patient’s clinical status.” The anticipated cost of each 
continuous blood gas monitor is $20,000 with a per probe 
cost close to $400. The indwelling probe will not obviate 
blood gas determinations that will have to be done at least 
every 24 hours for calibration. The total cost per 24 hour 
period, assuming one probe is in use and valuable for 72 
hours, will approximate the cost of four to five arterial 
blood gas determinations. If a probe is used for only 24 
hours, the cost becomes closer to that of seven to eight 
arterial blood gases. Finally, any cost-benefit analysis must 
take into consideration complication rate, such as arterial 
thrombus, increased nursing time to prevent or treat 
complications, and time required to maintain the equip- 
ment. 
In selected patients, the probes may prove to be cost- 
effective, although this evaluation cannot be made with any 
certainty until large-scale studies have been completed and 
the true costs are known. A clear concern is that the 
number of arterial blood gas determinations may not 
decrease despite the indwelling continuous probe. 
Puritan Bennett FOX-S Sensor. (FOXS Division, Carlsbad, 
CA). This sensor uses fluorescence to determine oxygen 
tension, and absorbance technology to determine pH and 
carbon dioxide tension. The analyzing dyes are impreg- 
nated in the surface cladding of the probe, and back from 
the tip (Fig 5) potentially correcting wall effect problems. 
The FOxS is currently available. Larson et al** evaluated 
nine probes used in critically ill patients and found a mean 
absolute drift of 3 to 6 mmHg for PO?, 4 to 7 mmHg for 
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PCOz, and 0.03 to 0.05 for pH measurement. No values arc 
reported for bias or precision. 
CDI-3M Healthcare System 2000. As noted above, Sha- 
piro et al presented their experience with this probe in 117 
patients with good results. More experience is available 
with a conceptually similar system, the (CDI, Irvine, CA), 
Gas-STAT a flow-through fluorometric system used to 
monitor blood gas values in the cardiopulmonary bypass 
circuit. Bashein et al29 and Pino et al3” reported results both 
in vitro and in vivo with the Gas-STAT system and 
concluded that whereas “the monitor is shown to be a 
valuable indicator of trends . . . its accuracy in the flow- 
through environment does not match its calibration perfor- 
mance and is insufficient to supplant traditional analyses of 
discrete samples for absolute measurements.” Peruzzi et 
alsi evaluated the CD1 2000 system in an unspecified 
number of patients and reported bias and precision values 
as follows: pH 0.004 ? 0.025, PO* 0.9 2 2.3 mmHg, and 
PC02 2.8 * 9.9 mmHg. 
Optex Biomedical Biosenty System. Rather than using 
glass fibers for light transmission, this sensor uses plastic 
fibers that may be bent 180” without breaking. The indicator 
dye chamber is located along the path of the light at the side 
of the probe (Fig 5C), again reducing thrombogenicity and 
decreasing wall effect problems. Zimmerman and Dellinger 
have presented their experience with this probe in five 
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patients as noted above,‘-1 and in other patients presented 
in non-peer-review literature.“? 
Pfizer Paratrend 7 (Pfizer Biomedical Sensors, Malvem, 
PA). This system uses a Clark polarographic electrode for 
determination of Pa02 and absorbance technology for 
determination of pH and PaC02. Early studies using 
miniaturized Clark electrodes, as noted above, experienced 
problems related to thrombus formation and interference 
with transduced pressures, presumably secondary to size of 
the electrode. No data exist in the literature to date on the 
in vivo performance of this system. 
SUMMARY 
The benefit of a continuous intra-arterial blood gas 
monitor is apparent to any physician who has ever waited 
for the return of blood gas values at the bedside of a 
critically ill patient. The potential for rapid detection and 
prompt treatment of blood gas changes, coupled with 
immediate evaluation of the effectiveness of a therapeutic 
intervention, appears great. Whereas these systems may 
offer a tremendous advance in the physician’s ability to 
track and treat alterations in cardiopulmonary physiology, 
no large-scale in vivo human trials have yet been reported. 
The only data available on accuracy, bias, precision, drift, 
and complication rate are from relatively small trials. 
Hopefully, when large-scale trials are completed, these 
systems will live up to their tremendous potential. 
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